139962-97-3

Basic information

• Product Name: 4-Benzyloxy-2-formylphenylboronic acid
• Synonyms: 3-BENZYLOXY-6-(DIHYDROXYBORONO)BENZALDEHYDE;4-BENZYLOXY-2-FORMYLPHENYLBORONIC ACID;AKOS BRN-0180;4-BENZYLOXY-2-FORMYLPHENYLBORONIC ACID,95%;Boronic acid, B-[2-formyl-4-(phenylmethoxy)phenyl]-;4-Benzyloxy-2-forMylphenyl acid;5-(Benzyloxy)-2-boronobenzaldehyde;4-Benzyloxy-2-formylphenylboronic Acid (contains varying amounts of Anhydride)
• CAS NO: 139962-97-3
• Molecular Formula: C₁₄H₁₃BO₄
• Molecular Weight: 256.06
• EINECS: 264-717-2
• Product Categories: Heterocyclic Compounds;Aryl;Ether;Organoborons
• Mol File: 139962-97-3.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 490.199 °C at 760 mmHg
• Flash Point: 250.264 °C
• Appearance: /
• Density: 1.263 g/cm³
• Vapor Pressure: 2E-10mmHg at 25°C
• Refractive Index: 1.599
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-Benzyloxy-2-formylphenylboronic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Benzyloxy-2-formylphenylboronic acid(139962-97-3)
• EPA Substance Registry System: 4-Benzyloxy-2-formylphenylboronic acid(139962-97-3)

Safety Data

• Hazard Codes: C,Xi
• Statements: 36/37/38-43-36
• Safety Statements: 26-36/37/39-36/37
• Hazardous Substances Data: 139962-97-3(Hazardous Substances Data)

Usage

Uses

suzuki reaction

InChI:InChI=1/C14H13BO4/c16-9-12-8-13(6-7-14(12)15(17)18)19-10-11-4-2-1-3-5-11/h1-9,17-18H,10H2

Upstream product

• 139962-96-2 5-Benzyloxy-2-bromobenzaldehyde diethyl acetal 
• 100-44-7 benzyl chloride 
• 1195-66-0 2-methoxy-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 2973-80-0 2-bromo-5-hydroxybenzaldehyde 
• 85604-06-4 5-(benzyloxy)-2-bromobenzaldehyde 

Downstream Products

• 139982-85-7 Methyl 4-benzyloxy-2-(4-benzyloxy-2-formylphenyl)-5-methoxybenzoate 
• 958030-50-7 3-cyclohexyl-2-[2-formyl-4-phenylmethoxy-phenyl]-1H-indole-6-carboxylic acid 1,1-dimethylethyl ester 
• 139963-03-4 1-<4-Hydroxy-3-(4-methoxycarbonylphenoxy)phenyl>-2-<5-hydroxy-2-(2-methoxycarbonyl-4-methoxyphenyl)phenyl>-ethane 
• 139963-08-9 1-<5-Hydroxy-2-(5-hydroxy-2-methoxycarbonyl-4-methoxyphenyl)phenyl>-2-<4-hydroxy-4-(4-methoxycarbonylphenoxy)phenyl>-ethane 
• 139963-06-7 1-<2-Benzyloxy-4-(4-bromomethylphenoxy)phenyl>-2-<5-benzyloxy-2-(2-bromomethyl-4-methoxyphenyl)phenyl>-ethane 
• 139963-05-6 1-<2-Benzyloxy-4-(4-hydroxymethylphenoxy)phenyl>-2-<5-benzyloxy-2-(2-hydroxymethyl-4-methoxyphenyl)phenyl>-ethane 
• 139963-04-5 1-<2-Benzyloxy-4-(4-methoxycarbonylphenoxy)phenyl>-2-<5-benzyloxy-2-(2-methoxycarbonyl-4-methoxyphenyl)phenyl>-ethane 
• 139962-91-7 2,13,20-Tribenzyloxy-15,6,17,18-tetrahydro-3-methoxy-7,10-etheno-12,16-metheno-16H-dibenzoxacyclooctadecin 
• 139963-10-3 1-<5-Benzyloxy-2-(5-benzyloxy-2-hydroxymethyl-4-methoxyphenyl)phenyl>-2-<4-benzyloxy-4-(4-hydroxymethylphenoxy)phenyl>-ethane 
• 139963-11-4 1-<5-Benzyloxy-2-(5-benzyloxy-2-bromomethyl-4-methoxyphenyl)phenyl>-2-<4-benzyloxy-4-(4-bromomethylphenoxy)phenyl>-ethane 
• 139963-09-0 1-<5-Benzyloxy-2-(5-benzyloxy-2-methoxycarbonyl-4-methoxyphenyl)phenyl>-2-<4-benzyloxy-4-(4-methoxycarbonylphenoxy)phenyl>-ethane 
• 139963-02-3 (E)- and (Z)-1-<4-Benzyloxy-3-(4-methoxycarbonylphenoxy)phenyl>-2-<5-benzyloxy-2-(2-methoxycarbonyl-4-methoxyphenyl)phenyl>-ethene 
• 139963-07-8 (E)- and (Z)-1-<5-Benzyloxy-2-(5-benzyloxy-2-methoxycarbonyl-4-methoxyphenyl)-phenyl>-2-<4-benzyloxy-4-(4-methoxycarbonylphenoxy)phenyl>-ethene 
• 1010688-69-3 C₃₃H₃₃NO₃ 

Relevant articles and documents

Design and enantioselective synthesis of 3-(α-acrylic acid) benzoxaboroles to combat carbapenemase resistance

Chiral 3-substituted benzoxaboroles were designed as carbapenemase inhibitors and efficiently synthesisedviaasymmetric Morita-Baylis-Hillman reaction. Some of the benzoxaboroles were potent inhibitors of clinically relevant carbapenemases and restored the activity of meropenem in bacteria harbouring these enzymes. Crystallographic analyses validate the proposed mechanism of binding to carbapenemases,i.e.in a manner relating to their antibiotic substrates. The results illustrate how combining a structure-based design approach with asymmetric catalysis can efficiently lead to potent β-lactamase inhibitors and provide a starting point to develop drugs combatting carbapenemases.

Identification of vimentin binding to the derivative of saurolactam with antiresorptive activity by using its chemical affinity probe

-